TrialPloS one2018

Randomised feasibility trial to compare three standard of care chemotherapy regimens for early stage triple-negative breast cancer (REaCT-TNBC trial).

John Hilton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.